Wall Street sell-side analysts are projecting Cancer Genetics, Inc. (NASDAQ:CGIX) to grow at an accelerated rate over the next 5 years. Brokerage firms are looking for the firm to grow 88.20% over the next year and 40.00% over the next five years.
Cancer Genetics, Inc. (NASDAQ:CGIX)’s trailing 12- months EPS is -1.16. Last year, their EPS growth was 49.20% and their EPS growth over the past five years was 23.70%.
Let’s start off by taking a look at how the stock has been performing recently. Over the past twelve months, Cancer Genetics, Inc. (NASDAQ:CGIX)’s stock was 188.89%. Last week, it was -1.27%, 8.33% over the last quarter, and 129.41% for the past half-year.
Over the past 50 days, Cancer Genetics, Inc. stock was -9.55% off of the high and 32.67% removed from the low. Their 52-Week High and Low are noted here. -24.91% (High), 261.82%, (Low).
Cancer Genetics, Inc. (NASDAQ:CGIX)’s performance this year to date is 188.89%. The stock has performed -1.27% over the last seven days, 2.63% over the last thirty, and 8.33% over the last three months. Over the last six months, Cancer Genetics, Inc.’s stock has been 129.41% and 88.86% for the year.
FUTURE GROWTH ESTIMATES AND RECOMMENDATIONS
Wall Street analysts are have a consensus analyst recommendation of 2.00 on the stock. This is based on a 1-5 scale where 1 represents a Strong Buy and 5 a Strong Sell. Brokerages covering the name have a $7.67 on the stock.
The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs. Where quoted, past performance is not indicative of future performance.